Brexpiprazole (Major Depressive Disorder) Market Opportunities, Trends and Challenges 2023

Brexpiprazole (Major Depressive Disorder) Market Size, Share, Trends,

Company Profiles, Demand, Insights, Analysis, Research, Report,

Opportunities, Segmentation and Forecast To 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide.

The MDD market is a crowded and competitive market, with more than 30 marketed products

available for the treatment of patients with MDD. The depression market is about to enter a

dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's

Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal

antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of

seven promising late-stage pipeline products into the market during the forecast period, from

2013 to 2023.

Otsuka Pharmaceutical initially developed Brexpiprazole but in 2011, the pharmaceutical

company entered an agreement with Lundbeck for the co-development and co-commercialization

of this product. The product is in Phase III development as an adjunctive therapy for MDD in the

US and Europe, and is also being developed for the treatment of schizophrenia, anxiety

disorders, dementia, post-traumatic stress disorder (PTSD), sleep disorders, and ADHD.

Browse the full “Brexpiprazole Market” report at:

http://www.radiantinsights.com/research/brexpiprazole-major-depressive-disorderforecast-and-market-analysis-to-2023

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms,

diagnosis, pathology and treatment guidelines as well as an overview on the competitive

landscape.

- Detailed information on Brexpiprazole including product description, safety and efficacy

profiles as well as a SWOT analysis.

- Sales forecast for Brexpiprazole for the top eight countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and

Australia.

Reasons to buy

- Understand and capitalize...